Drug Profile
Research programme: bispecific antibodies - EpimAb Biotherapeutics
Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Epimab Biotherapeutics
- Developer EpimAb Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
- 24 Apr 2019 EpimAb Biotherapeutics has patent protection for bispecific antibodies obtained utilizing the FIT-Ig® technology in USA
- 25 Apr 2017 EpimAb's Bispecific antibodies programme is available for licensing; (http://www.epimab.com/partnering/)